8-K: Oncotelic Therapeutics Announces Positive Phase 1 Trial Results for OT-101 and IL-2 Combination Therapy

Oncotelic Therapeutics reports successful completion of a Phase 1 clinical trial of OT-101 combined with IL-2 for advanced or metastatic solid tumors, paving the way for further studies with checkpoint inhibitors.

Summary

• Oncotelic Therapeutics announced the successful completion of a Phase 1 clinical trial evaluating OT-101 in combination with IL-2 for patients with advanced or metastatic solid tumors.
• The trial demonstrated a tolerable safety profile for the combination therapy at the planned dosing schedule, with no unexpected safety signals.
• Based on these results, Oncotelic plans to advance OT-101 plus IL-2 into further clinical studies, exploring synergies with checkpoint inhibitors such as PD-1 blockers.
• Dr. Vuong Trieu, Chairman & CEO of Oncotelic, presented at the 5th Symposium on World Cancer Research (SWCR) 2025, highlighting the role of TGF2 in immune suppression and the development of OT-101 in various cancers.
• OT-101 is currently in a Phase 3 clinical trial (STOP-PC study) for pancreatic ductal adenocarcinoma (PDAC) in combination with mFOLFIRINOX.
• The company is also exploring OT-101's potential in gliomas, where high intratumoral TGF2 expression correlates with poor prognosis.
• Oncotelic intends to use a new PDAOAI public Discord server to share information and engage with the public using a proprietary chatbot technology.

Sentiment

Score: 7

Explanation: The document presents positive results from a Phase 1 trial and outlines future plans for clinical development. While forward-looking statements involve risks, the overall tone is optimistic and suggests potential for future success.

Positives

• Successful completion of Phase 1 clinical trial of OT-101 and IL-2.
• Tolerable safety profile observed in the Phase 1 trial.
• Plans to advance OT-101 plus IL-2 into further clinical studies with checkpoint inhibitors.
• OT-101 is in a Phase 3 trial for pancreatic cancer.
• Exploration of OT-101's potential in gliomas.
• Launch of a PDAOAI public Discord server for public engagement.

Risks

• The document contains forward-looking statements that involve substantial risks and uncertainties.
• Actual results could differ materially from those contained in any forward-looking statement due to various factors, including those described in the company's filings with the SEC.
• Unexpected safety or efficacy data observed during preclinical or clinical studies could impact the development of OT-101.
• Clinical trial site activation or enrollment rates that are lower than expected could delay the progress of clinical trials.
• Changes in the regulatory environment could affect the approval and marketing of the company's products.
• Failure of collaborators to support or advance collaborations or product candidates could impact the company's progress.
• Unexpected litigation or other disputes could negatively affect the company's financial position.

Future Outlook

Oncotelic plans to advance OT-101 plus IL-2 into further clinical studies, exploring synergies with CKIs such as PD-1 blockers, and to begin further combination trials to determine the added efficacy of OT-101, IL-2, and CKIs in solid tumors such as lung cancer, melanoma, and colorectal cancer.

Management Comments

• 'Our findings reinforce that OT-101s specific inhibition of TGF2 can significantly enhance the immune response, and we are eager to test these synergies with checkpoint inhibitors and IL-2 to maximize therapeutic potential for patients with hard-to-treat cancers,' said Dr. Vuong Trieu, Chairman & CEO of Oncotelic.
• 'We are excited to bring PDAOAI to the public and are excited for the user feedback,' said Scott Myers, Product Manager.
• 'This presentation is a beginning to bringing our AI technology to the masses and not just our internal team.'

Industry Context

The announcement highlights the growing interest in combination immunotherapies for cancer treatment, particularly those targeting TGF2 and utilizing checkpoint inhibitors and IL-2. This approach aligns with the broader industry trend of exploring synergistic combinations to overcome immune evasion mechanisms in tumors.

Comparison to Industry Standards

• Many pharmaceutical companies are exploring combination therapies involving IL-2 and checkpoint inhibitors to enhance anti-tumor immune responses.
• Companies like Bristol Myers Squibb and Merck are actively involved in developing and marketing checkpoint inhibitors, which are often combined with other immunotherapies.
• The Phase 3 STOP-PC study of OT-101 in pancreatic cancer is comparable to other late-stage clinical trials evaluating novel therapies for this difficult-to-treat disease.
• The use of AI-powered chatbots for investor relations and public engagement is becoming increasingly common in the biotech industry, with companies like Relay Therapeutics and Recursion Pharmaceuticals utilizing similar technologies.

Stakeholder Impact

• Shareholders: Positive results from the Phase 1 trial could increase investor confidence.
• Patients: Successful development of OT-101 could provide a new treatment option for advanced or metastatic solid tumors.
• Employees: Advancement of clinical trials could create new opportunities within the company.
• Collaborators: Continued collaboration could lead to further advancements in cancer treatment.

Next Steps

• Advance OT-101 plus IL-2 into further clinical studies, exploring synergies with CKIs such as PD-1 blockers.
• Begin further combination trials to determine the added efficacy of OT-101, IL-2, and CKIs in solid tumors such as lung cancer, melanoma, and colorectal cancer.
• Continue the Phase 3 STOP-PC study for pancreatic ductal adenocarcinoma (PDAC).
• Explore OT-101's potential in gliomas.
• Utilize the PDAOAI public Discord server to share information and engage with the public.

Key Dates

Keywords

OT-101, IL-2, TGF2, Oncotelic Therapeutics, Phase 1 clinical trial, Cancer, Immunotherapy, Checkpoint inhibitors, Solid tumors, PDAOAI